Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Immuno-oncology in Breast Cancer Early Promise
*Corresponding Author:
Copyright: © 2019 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
According to data published in 2013, breast cancer (BrCa) is not a disease that harbors high mutational load; nevertheless, it seems that triple negative (TN) BrCa which by itself is a heterogenous group may show much higher rates of mutations than hormone receptor (HR) positive BrCa. These mutations in turn might lead to a higher level of neoantigens which are antigenic and can induce an immune response in the host. This concept, has led investigators to design several clinical trials using immune checkpoint inhibitors (ICI) in early (ECB) and metastatic (MBC) BrCa. Unlike in other cancers, there are no ICI approved in this space yet. Several trials in EBC and MBC using ICI in combination will be reported this year which will hopefully result in advancing therapy and improving patients’ outcomes.
